Adherence and blood pressure control in patients with primary aldosteronism

References

• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. J Hypertens. 2018;36(10):1953–2041.
   PubMed Web of Science ®Google Scholar
• Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124–1140.
   PubMed Web of Science ®Google Scholar
• Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68(2):297–306.
   PubMed Web of Science ®Google Scholar
• Lane D, Lawson A, Burns A, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension. 2022;79(1):12–23.
   PubMed Web of Science ®Google Scholar
• Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23(11):2093–2100.
   PubMed Web of Science ®Google Scholar
• Bautista LE. Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens. 2008;21(2):183–188.
   PubMed Web of Science ®Google Scholar
• Gupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69(6):1113–1120.
   PubMed Web of Science ®Google Scholar
• Ceral J, Habrdova V, Vorisek V, et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87–90.
   PubMed Web of Science ®Google Scholar
• Eskås PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199–205.
   PubMed Web of Science ®Google Scholar
• Strauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455–2461.
   PubMed Web of Science ®Google Scholar
• Velasco A, Chung O, Raza F, et al. Cost-Effectiveness of therapeutic drug monitoring in diagnosing primary aldosteronism in patients with resistant hypertension. J Clin Hypertens. 2015;17(9):713–719.
   Web of Science ®Google Scholar
• Sandbaumhüter FA, Haschke M, Vogt B, et al. Medication adherence during laboratory workup for primary aldosteronism: pilot study. Patient Prefer Adherence. 2018;12:2449–2455.
   PubMed Web of Science ®Google Scholar
• Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2009;94(10):3623–3630.
   PubMed Web of Science ®Google Scholar
• Rossi GP. Primary aldosteronism: JACC state-of-the-Art review. J Am Coll Cardiol. 2019;74(22):2799–2811.
   PubMed Web of Science ®Google Scholar
• Overdiek HW, Hermens WA, Merkus FW. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther. 1985;38(4):469–474.
   PubMed Web of Science ®Google Scholar
• Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916.
   PubMed Web of Science ®Google Scholar
• Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens. 2020;38(10):1919–1928.
   PubMed Web of Science ®Google Scholar
• Iriarte G, Gonzalez O, Ferreirós N, et al. Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(27):3045–3053.
   PubMed Web of Science ®Google Scholar
• Gonzalez O, Iriarte G, Rico E, et al. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(28):2685–2692.
   PubMed Web of Science ®Google Scholar
• Dong H, Xu F, Zhang Z, et al. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS. J Mass Spectrom. 2006;41(4):477–486.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Fast DM, Breau AP. Development and validation of a liquid chromatography-tandem mass spectrometric assay for eplerenone and its hydrolyzed metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;787(2):333–344.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. 2020. Available from: https://www.r-project.org/
   Google Scholar
• Bergland OU, Halvorsen LV, Søraas CL, et al. Fadl elmula FEM. Detection of nonadherence to antihypertensive treatment by measurements of serum drug concentrations. Hypertension. 2021;78(3):617–628.
   PubMed Web of Science ®Google Scholar
• Ishida T, Oh A, Hiroi S, et al. Treatment patterns and adherence to antihypertensive combination therapies in Japan using a claims database. Hypertens Res. 2019;42(2):249–256.
   PubMed Web of Science ®Google Scholar
• Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact. 1987;5(4):273–302.
   PubMedGoogle Scholar
• Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the american heart association. Hypertension. 2022;79(1):e1–e14.
   PubMed Web of Science ®Google Scholar
• Šíma M, Vodička M, Marešová V, et al. Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. Int J Clin Pharm. 2017;39(5):1095–1100.
   PubMed Web of Science ®Google Scholar
• Born-Frontsberg E, Reincke M, Rump LC, et al. Participants of the german conn's registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the german conn's registry. J Clin Endocrinol Metab. 2009;94(4):1125–1130.
   PubMed Web of Science ®Google Scholar
• Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31(1):3–15.
   PubMed Web of Science ®Google Scholar
• Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol. 1999;48(5):756–760.
   PubMed Web of Science ®Google Scholar
• Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980–990.
   PubMed Web of Science ®Google Scholar
• Steichen O, Lorthioir A, Zinzindohoue F, et al. Outcomes of drug-based and surgical treatments for primary aldosteronism. Adv Chronic Kidney Dis. 2015;22(3):196–203.
   PubMed Web of Science ®Google Scholar